Gouju Julien, Jourdan Charles, Legeay Samuel
Inserm U1066, MINT, CNRS 6021, SFR-ICAT 4208, IBS, CHU d'Angers, université d'Angers, 49933 Angers, France; CHU d'Angers, 49933 Angers, France.
SAS EmaSofts, 49000 Angers, France.
Therapie. 2024 May-Jun;79(3):379-392. doi: 10.1016/j.therap.2023.07.004. Epub 2023 Jul 28.
Between 1975 and 2014, the number of people suffering from obesity tripled, reaching 17% of the adult population in France and more than 35% in the United States. Obesity is defined by a Body Mass Index (BMI)>30kg/m and characterized by a significant accumulation of adipose tissue responsible for the increase in weight. This accumulation leads to physiological changes capable of modifying the pharmacokinetics of drugs, which can lead to the administration of inappropriate doses. For this reason, some significant dosage adjustments are necessary for obese patients. However, data on these adaptations are not easily accessible and sometimes complex to implement in practice.
To perform a new online tool allowing to calculate and propose an adjusted dose of a drug that should be administered to an obese patient.
(i) carrying out an extensive bibliographic research according to the PRISMA methodology; and (ii) the development of a new website site proposing an adjusted dose for obese patients.
Firstly, 49 reviews concerning the dose adaptation have been evaluated and, secondly, 319 articles have been selected. Among them, 204 articles have been included in the database to justify the adjusted dose of 84 drugs and administration methods including antibiotics, antifungals, anticoagulants or even cancer drugs. This database is available online through a calculator on the website named Adapt'Obese. Thus, with the sex, height and weight of an obese patient, Adapt'Obese proposes a personalized and adjusted dose of the drug to administer.
Other drugs will be added soon, and functional improvements are planned, with the aim of adapting the dosages in obese patients, as for patients with renal insufficiency.
